Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a global leader in orthobiologics, committed to providing innovative solutions that enhance the body’s natural healing processes. The company offers a comprehensive array of medical technology products designed to support musculoskeletal healing, including orthobiologic treatments, surgical solutions, and pain management therapies.
Founded in 2012 and headquartered in Durham, North Carolina, Bioventus has grown to employ nearly 600 professionals worldwide, with international offices in Hoofddorp, the Netherlands; Memphis, Tennessee; Australia; Canada; and a research and development site in Boston. The company’s mission is to help patients resume and enjoy active lives by delivering clinically proven, cost-effective products that ensure quick and safe recovery.
Bioventus operates through two main product portfolios: Bioventus Active Healing Therapies and Bioventus Surgical. These portfolios are enhanced through internal product development, strategic acquisitions, and distribution agreements. Their diverse range of products spans various medical specialties, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery.
Financially, Bioventus has demonstrated resilience and growth, reporting in its latest quarterly results a robust increase in adjusted EBITDA and significant improvements in cash flow and operating income. Despite a slight dip in total net sales, the company saw strong volumes in Surgical Solutions and substantial growth in its international markets.
Recent highlights include management’s focused efforts to stabilize operations, enhance liquidity, and maintain spending discipline. This strategic approach has positioned Bioventus to accelerate revenue growth and create long-term value for its stakeholders. The company continues to be a trusted partner to physicians and healthcare providers globally, offering high-quality, evidence-based medical solutions.
Bioventus (Nasdaq: BVS) announced the appointment of Mark Singleton as Senior Vice President and Chief Financial Officer, effective March 21, 2022. Singleton, who has over 20 years of experience in finance and operational roles, previously served at Teleflex, overseeing a $1.7 billion business. CEO Ken Reali stated that Singleton's experience and leadership qualities will enhance Bioventus' operational efficiencies and market leadership. Singleton expressed excitement about leveraging the company’s portfolio to drive growth and improve operating margins.
Bioventus (Nasdaq: BVS) announced it will report its financial results for Q4 and fiscal year 2021 on March 10, 2022, before the market opens. A conference call hosted by management will follow at 8:30 a.m. Eastern Time to discuss the results and provide a business update. The call can be accessed via phone or through a live webcast on the Investor Relations section of Bioventus' website. The webcast will be available for replay until March 9, 2023.
SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.
Bioventus (Nasdaq: BVS) announced preliminary revenue results for Q4 and full-year 2021, projecting revenues between $128.5 to $131.5 million for Q4, marking a 30% to 33% growth year-over-year, and $429 to $432 million for the full year, an increase of approximately 34%. CEO Ken Reali expressed pride in the team’s performance despite market challenges, highlighting strong growth in Pain Treatments and Bone Graft Substitutes. The company anticipates that recent acquisitions will meet or exceed expectations as it heads into 2022.
DURHAM, N.C., Dec. 28, 2021 – Bioventus (Nasdaq: BVS) announced that CEO Ken Reali will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 p.m. ET. The presentation will be accessible via a live webcast on the Bioventus investors website, and it will also be archived for later viewing. Bioventus is dedicated to providing innovative, clinically proven products that facilitate active healing and enhance patient recovery.
Bioventus (Nasdaq: BVS) has appointed Dr. Michelle McMurry-Heath to its Board of Directors, effective January 1, 2022. With over 20 years of experience in healthcare and regulatory roles, McMurry-Heath brings valuable insights to the company. Her previous positions include leading regulatory science at Johnson & Johnson and serving at the FDA. Bioventus aims to leverage her expertise in medical innovation and regulatory affairs to advance its offerings in pain treatment and restorative therapies. Company leadership expresses optimism about the strategic guidance she will provide.
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece, enhancing minimally invasive surgery with improved bone removal capabilities. This device, part of the neXus Ultrasonic Surgical Aspirator System, offers surgeons greater control and versatility. The launch is anticipated in 2022, with the system already commercialized in several countries. The BoneScalpel Access is indicated for use across various surgical specialties, indicating a broad application potential.
Bioventus (Nasdaq: BVS) announced a lease agreement to expand its operational and manufacturing space in Memphis, doubling its current area. The new facility, located at 7101 Goodlett Farms Parkway in Cordova, TN, features approximately 90,000 square feet, with 55,000 dedicated to manufacturing. This move is set for early Q3 2022 and will create an additional 40 jobs over five years. The expansion aligns with the company’s strategy for organic growth and vertical integration, enhancing its manufacturing capabilities.
Bioventus (Nasdaq: BVS) announced the departure of Greg Anglum from his role as CFO, effective immediately. Anglum will remain until a successor is identified. CEO Ken Reali praised Anglum for his contributions over five years, including during the IPO and recent acquisitions. The company reassures stakeholders that his departure is not due to business performance issues, reaffirming its financial guidance for 2021. Bioventus is actively seeking a new CFO to support its growth strategy.
Bioventus Inc. (Nasdaq: BVS) reported Q3 2021 net sales of $108.9 million, up 26.8% year-over-year, driven by strong commercial execution and acquisitions. The company generated a net loss of $2.3 million, down from net income of $8.0 million in Q3 2020. Adjusted EBITDA was $21.3 million, a decline of 7.7% year-over-year. Bioventus updated its full-year sales guidance to $425-$430 million, reflecting 32% to 34% growth. The company successfully integrated Bioness and completed the acquisition of Misonix, positioning itself for further growth in the healing innovations sector.
FAQ
What is the current stock price of Bioventus (BVS)?
What is the market cap of Bioventus (BVS)?
What does Bioventus Inc. specialize in?
Where is Bioventus Inc. headquartered?
What are the main product portfolios of Bioventus?
How does Bioventus improve its product offerings?
What medical specialties does Bioventus cater to?
What recent financial achievements has Bioventus made?
What is the mission of Bioventus?
How does Bioventus contribute to patient care?
What are Bioventus’s strategic priorities?
How is Bioventus positioned in the global market?
